Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

In a report released yesterday, Carter Gould from Barclays maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), with ...

On Wednesday, 2Seventy Bio Inc (TSVT) stock saw a decline, ending the day at $4.32 which represents a decrease of $-0.45 or -9.43% from the prior close of $4.77. The stock opened at $4.32 and touched ...

Will peptide-drug conjugates become the "next big thing" in targeted cancer therapy? (Endpoints News) Bristol Myers Squibb ...

Wegovy is approved for obesity but is also under investigation in a range of other indications. Image credit: Shutterstock / KK Stock. Novo Nordisk’s Wegovy has shown promising benefits in treating a ...

This news brief covers various health-related updates including Washington state's abortion pill stockpile, EPA regulations on fluoridated water, radiation exposure in spaceflight, BioAge Labs' IPO, ...

NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma ...

Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...